Technical analysis of Onconetix, Inc. (ONCO): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH).
Price Performance
| 1 month | -11.58% |
| 3 months | -29.72% |
| Year-to-date | -99.15% |
| 1 year | -99.58% |
| 3 years | -100.00% |
52-Week Range
| 52-week High | $209.50 |
| 52-week Low | $0.59 |
| Avg Volume (90d) | 790K |
Technical Indicators
| SMA 50 | $0.80 |
| SMA 200 | $29.90 |
| 30-day Volatility (annualised) | 148.4% |
| Price vs SMA 50 | -16.6% |
| Price vs SMA 200 | -97.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $169.50 | |
| 2025-11 | $139.00 | -18.0% |
| 2025-12 | $78.00 | -43.9% |
| 2026-01 | $71.00 | -9.0% |
| 2026-02 | $33.50 | -52.8% |
| 2026-03 | $14.90 | -55.5% |
| 2026-04 | $6.95 | -53.4% |
| 2026-05 | $1.20 | -82.7% |
| 2026-06 | $1.13 | -5.8% |
| 2026-07 | $0.83 | -26.8% |
| 2026-08 | $0.63 | -24.2% |
| 2026-09 | $0.66 | +5.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $0.66 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.11 |
| EV / EBITDA | 0.21 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 2.21 |